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Effect of cisplatin on the transepithelial potential difference of
rat distal tubule
GLEN G. ALLEN and LINDSAY J. BARRATT
Renal Unit, Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia
Effect of cisplatin on the transepithelial potential difference of the distal
tubule of the rat kidney. Cisplatin, an effective anti-tumor agent, has
significant effects on renal function including reduced glomerular filtra-
tion rate and potassium and magnesium wasting. It has been shown
recently that cisplatin increases sodium conductance across the isolated
frog skin, an effect which was inhibited by amiloride. The present study
investigates the influence of cisplatin on the transepithelial potential
difference (PD) of distal nephron segments of the rat kidney. Measure-
ments were made under free-flow conditions and during distal
microperfusion. When cisplatin was infused intravenously in a dose of
2 mg/kg/br, the mean free-flow PD in late distal segments (cortical
collecting tubules) increased from —18.5 1.4 mV (N = 37) to —31.2
1.4 mV (N = 36) (P < 0.001). The large negative PD seen with cisplatin
was abolished with intravenous amiloride, a mean n of +0.9 1.5 mV
(N = 22) (P <0.001) being obtained, similar to a PD of +1.9 1.5 mY(N = 39) found in control animals infused with amiloride. Perfusion of
individual late distal segments with artificial plasma ultrafiltrate yielded
a mean control PD of —12.4 1.2 mY (N = 21)and a significantly higher
PD of —17.5 1.5 mV (N = 24) (P <0.01) when cisplatin (10 M) was
added to the perfusate. The addition of amiloride to these perfusates
reduced the mean PD5 to —3.2 0.5 mV (N = 19) and —3.6 0.7 mV(N = 17), respectively. Cisplatin had no effect on the PD of early distal
segments under either free-flow or microperfusion conditions. In con-
clusion, (1) cisplatin increases the magnitude of the negative PD in late
distal segments of the rat kidney but does not influence the early distal
PD, and (2) amiloride prevents the cisplatin-induced PD change in the
late distal tubule.
Effet du cisplatine sur Ia difference de potentiel transépithélial du
tubule distal de rein de rat. Le cisplatine, un agent anti-tumoral actif, a
des effets significatifs sur la fonction rénale, notamment induit une
reduction de debit de glomdrulaire filtration (GFR) et une fuite de
potassium et de magnesium. II a récemment été montré que Ic cisplatine
augmente Ia conductance du sodium a travers Ia peau de grenouille,
effet qui est inhibé par l'amiloride. Ce travail étudie l'influence du
cisplatine sur Ia difference depotentiel (pn) transpethelial de segments
de nephron distal du rein de rat. Les mesures ont été faites dans des
conditions de flux libre et pendant une microperfusion distale. Quand le
cisplatine était perfuse par voie intraveineuse a la dose de 2 mg/kg/hr, la
PD moyenne en flux libre dans les segments distaux terminaux (tubules
collecteurs corticaux) s'dlevait de —18,5 1,4 mV (N = 37) a —31,2
1,4 mY (N = 36) (P < 0,001). La forte PD negative observde avec le
cisplatine était abolie avec de l'amiloride intraveineux, une PD moyenne
de + 0,9 1,5 mY (N = 22) (P < 0,001) etant obtenue, identique a une
PD de + 1,9 1,5 mY (N = 39) trouvée chez des animaux contrôles
perfuses avec de l'amiloride. La perfusion de segments distaux
terminaux individuels avec un ultra filtrat de plasma artificiel a donnd
une PD controle moyenne de —12,4 1,2 mV (N = 21) et une PD
significativement plus élevée de —17,5 1,5 mV (N = 24) (P < 0,01)
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Iorsque le cisplatine (10-s M) était ajoutC au perfusat. L'adjonction
d'amiloride a ces perfusats a reduit les PD moyennes a —3,2 0,5 mV(N = 19)et —3,6 0,7 mV (N = 17), respectivement. Le cisplatine était
sans effet sur Ia PD de segments distaux initiaux en condition de flux
libre ou de microperfusion. Dans conclusions, (1) le cisplatine augmente
l'amplitude de Ia PD negative dans les segments distaux terminaux du
rein de rat, mais n'influence pas la PD distale initiale, et (2) l'amiloride
prdvient les changements de PD induits par le cisplatine dans Ic tubule
distal terminal.
Cisplatin (dichlorodiammine platinum II), a modern and
effective anti-tumor agent [1], unfortunately possesses potent
nephrotoxic properties [2—4]. Histological studies have demon-
strated cisplatin-induced cell damage in both proximal and
distal tubules [5—8] while functional studies have shown re-
duced glomerular filtration rate (GFR) [2, 8], impaired renal
concentrating capacity [7, 9], and potassium and magnesium
wasting [6, 10—12].
These functional defects imply that cisplatin affects various
renal transport processes, but these have not yet been studied
in detail. However, in a recent in vitro study, van den Berg et
al [13] examined the effects of cisplatin onion movement across
the isolated frog skin, an epithelium often regarded as the
amphibian equivalent of the mammalian distal nephron.
Cisplatin was shown to act on the outer surface of this epi-
thelium increasing short-circuit current, transepithelial con-
ductance of sodium and chloride ions, and transepithelial po-
tential difference (PD). This effect of cisplatin was blocked by
amiloride, suggesting that the cisplatin-induced increase in
sodium conductance occurred via an amiloride-sensitive so-
dium pathway.
On the basis of these findings in the frog skin, the present in
vivo micropuncture study was designed to assess the effects of
cisplatin and amiloride on the transepithelial PD of both early
and late distal segments of the rat kidney. Our results indicate
an effect of cisplatin on the PD of late distal tubules (cortical
collecting tubules) consistent with that observed in the frog
skin, but no effect on early distal tubules.
Methods
Studies were performed on 32 male members (body weight,
150 to 250 g) of a locally inbred strain of Ginger-hooded rats
anesthetized with intraperitoneal mactin (Promonta, Germany)
and prepared for micropuncture of the left kidney as described
previously [14—16]. Ringers bicarbonate solution was the basic
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infusate used and was administered intravenously at a rate of
0.1 mllmin throughout the experiment. Potential difference
measurements were commenced after 1 hr of constant infusion
of Ringers bicarbonate solution. In groups 1 to 4 (see below)
PDS were measured only under free-flow conditions, whereas in
groups 5 and 6, PDS were measured during distal microperfusion
as well as under free-flow conditions.
Electrical measuring system
Large-tip microelectrodes (3 to 6 m O.D.) were used for PD
measurement in this study. The validity of transepithelial PD
measurements made with large-tip microelectrodes has been
questioned previously with suggestions of increased electrical
shunting [17] and apical membrane depolarization arising from
movement of tubular fluid into the pipette tip [18]. However, it
has been shown that in the distal tubule, transepithelial resist-
ances are almost identical during micropuncture with either
large-tip or Ling Gerard (<1 m O.D.) electrodes [15]. Hence
the possibility of excessive voltage shunting with large-tipped
microelectrodes appears unlikely. Furthermore, a recent study
evaluating the use of large-tipped microelectrodes for PD mea-
surements in the early distal tubule found no evidence of
depolarization of the apical membrane when tubular fluid was
aspirated deliberately into the tip of these electrodes during PD
recordings [19]. In this same study, the early distal tubule was
found to have a mean PD of +6.8 mY when measurements were
made with large-tipped microelectrodes. A similar PD of +7.2
mY was obtained when Ling Gerard electrodes, filled with
artificial early distal fluid, were used for PD measurements in the
same segments. Considering these data and because large-
tipped microelectrodes are not complicated by unpredictable tip
potentials and they are easy to localize intraluminally during
tubular puncture, we chose to use them for PD measurements in
the present study.
Details of the electrical circuit and the standard techniques
used in transepithelial PD measurements have been described in
previous publications [14—16].
Free-flow
Potential difference measurements
Free-flow transepithelial PD measurements were made with 3
M potassium chloride-filled large-tip microelectrodes (tip size, 3
to 5 pm O.D.)
Distal microperfusion
Electrical shunting was minimized by using a single 3 to 6 m
tip pipette for both microperfusion and PD measurement. The
pipette, filled with artificial plasma ultrafiltrate (colored with
0.16% FD and C green dye no. 3, Keystone, Chicago, Illinois,
USA), was held in a microperfusion apparatus (Hampel), the
barrel of which contained 3 M KC1. A AgIAgCl electrode was
inserted into the 3 M KC1-containing barrel via a specially
designed leak-proof sidearm. This electrode was connected to
the input of an electrometer (model 602, Keithley Instruments,
Cleveland, Ohio, USA). The remainder of the electrical cir-
cuitry has been described in detail previously [14—16].
Microelectrodes were tested in vitro for streaming potentials
arising from microperfusion per se and were discarded if
Table 1. Composition of artificial plasma ultrafiltrate (APU) used in
microperfusion experiments
Cations
mmoles/liter
Anions
mmoles/liter
Sodium 148 Chloride 112
Potassium 5 Bicarbonate 25
Magnesium 1 Hydrogen phosphate 4
Calcium I Acetate
Sulphate
10
1
Mannitol 12
Osmolality 300 mOsm/kg
pHa 7•4
a The pH is adjusted by bubbling a 5% C02/02 gas mixture into the
perfusate for approximately 30 mm.
microperfusion at 55 nllmin resulted in a PD change of greater
than 0.5 mY.
Distal segments were identified by injecting a small quantity
of Ringers bicarbonate solution colored with 0.2% FD and C
green dye no. 3 into a segment of proximal tubule. Early and
late distal loops were localized by observing the passage of the
dye-colored fluid through surface convolutions of the distal
tubule of the same nephron. We have shown previously that
early distal segments represent distal convoluted tubules while
late segments represent cortical collecting tubules [15, 20].
A proximal segment of the same nephron was then punctured
by a second pipette (tip, 8 to 10 m O.D.) containing Sudan
black-stained castor oil. Subsequently, the microperfusion elec-
trode was positioned in the identified distal segment and the
free-flow PD recorded with the perfusate: tubular fluid interface
within the tip of the electrode. Following this measurement,
distal microperfusion was commenced at 55 nl/min. We have
demonstrated previously that the transepithelial PD across
perfused distal segments does not change significantly with
variations in the perfusion rate between 5 and 55 nI/mm [211.
A long oil block was introduced through the proximally
placed pipette to prevent proximal to distal flow and the tubular
fluid was then collected continuously into the same pipette. The
PD was recorded again under these conditions of distal
microperfusion. PD values were accepted as valid and satisfac-
torily stable if a maximum variation of 3 mV occurred over a
minimum period of 20 sec.
Pipettes were filled with one of four perfusates (APU, APU
plus i03 M cisplatin, APU plus l0 M amiloride, or APU plus
l0 M cisplatin and l0— M amiloride); the basic solution in
each instance was artificial plasma ultrafiltrate (APU) whose
composition is shown in Table 1. This solution was chosen to
minimize ionic and osmotic concentration gradients across the
tubular wall and hence any PD arising from this perfusate should
indicate the presence of active ionic transport.
Free-flow studies
Experimental groups
Group 1: effect of cisplatin (six rats). Transepithelial PD
measurements were made in both early and late distal segments
under free-flow conditions during an initial control period of
Ringers bicarbonate infusion and subsequently during an ex-
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perimental period of infusion of cisplatin in Ringers bicarbonate
solution at an infusion rate of 2 mg/kg/hr after an initial bolus
dose of 2 mg/kg given intravenously. This dose was based on
that used in previous studies by Leonard, Eccleston, and Jones
22] and Ward and Fauvie 231. At least 1 hr was allowed to
elapse after cisplatin infusion was begun before distal PD
measurements were resumed.
Group 2: effect of cisplatin plus amiloride (six rats), This
group received an initial infusion with cisplatin in Ringers
bicarbonate solution using an identical dosage regimen to that
described for group 1. After distal PD measurements had been
made during this period, the infusate was changed to contain
both amiloride (2 mg/kg/hr) and cisplatin (2 mg/kg/hr) in Ringers
bicarbonate. A bolus dose of amiloride (1 mg/kg) was given at
the beginning of this period. Potential difference measurements
were resumed at least 60 mm after the start of this infusion.
Group 3: effect of amiloride alone (four rats). Distal PD
measurements were made during an initial control period of
Ringers bicarbonate infusion, and during an experimental pe-
riod of intravenous administration of amiloride (2 mg/kg/hr) in
Ringers bicarbonate. A bolus dose of 1 mg/kg of amiloride was
injected at the beginning of the experimental period.
Group 4: "time controls." Effect of Ringers bicarbonate
infusion without drugs (Thur rats). The animals were infused
intravenously with Ringers-bicarbonate fluid throughout the
entire experiment covering a time span equal to both control
and experimental periods of previous groups. Distal PD mea-
surements were made at appropriate "control" and "experi-
mental" times.
Microperfusion studies
Group 5: effect of cisplatin (six rats). Distal PD measurements
were made during distal tubule microperfusion with either APU
or APU plus cisplatin (Table 1). Ringers bicarbonate was
infused throughout the experiments. An equilibration period of
at least 1 hr of constant infusion of Ringers bicarbonate was
maintained before PD measurements were commenced.
Group 6: effect of amiloride plus cisplatin (six rats). In these
experiments the two perfusates used were APU plus amiloride
and APU plus amiloride and cisplatin (Table 1).
Statistical analysis of data
Standard variance analysis was used to determine differences
between control and experimental periods and between groups
241. All results are expressed as the mean I standard error of
the mean (sEM).
Free-flow studies
Results
Group 1: effect of cisplatin. In the control period, the mean
transepithelial PD in early distal segments was +6.6 0.6 mV
(N = 29) and the mean PD in late distal segments was —18.5
1.4 mV (N = 37). These values are similar to those previously
reported from our laboratory [201. Infusion of cisplatin did not
significantly change the mean free-flow PD in early segments,
yielding a value of +5.9 0.5 mV (N = 45), but significantly
increased the mean late distal PD to —31.2 1.4 mV (N = 36,
P < 0.001, Fig. 1).
Control period (C) Experimental period (E)
Fig. 1. Summwy of changes in mean early and late distal free-flow PD
values (mean SEM) from control to experimental periods in groups 1
to 4. Symbols are: •—•, group I, control Ringers bicarbonate,
experimental cisplatin; A—A group 2, control cisplatin, experimental
cisplatin and amiloride; •—U, group 3, control Ringers bicarbonate,
experimental amiloride; 0—0, group 4, control Ringers bicarbonate,
experimental Ringers bicarbonate; P values refer to experimental
versus control readings; *, the late distal PD5 found during the experi-
mental periods of groups 2 and 3 did not differ significantly.
Group 2: effect of cisplatin plus amiloride. The mean early
segment PD in this group during the control period of cisplatin
infusion was +7.4 0.7 mY (N = 18) whereas the mean late
segment PD in the same period was —34.8 2.0 mV (N = 20).
These results are similar to those obtained during the experi-
mental period of cisplatin infusion in group 1 animals. When
amiloride was infused in addition to cisplatin during the experi-
mental period, the early segment PD increased significantly to
+ 10.7 0.6 mY (N = 27, P < 0.001) while the large negative
late distal PD was reduced to a value not significantly different
from zero, that is, +0.9 1.5 mV (N = 22, P < 0.001, Fig. 1).
Group 3: effect of amiloride alone. The mean PD in early
distal segments was +7.7 0.7 mY (N = 31), and in late
segments it was —19.8 1.9 mV (N = 23) during the control
period of Ringers bicarbonate infusion, similar to the control
values recorded in group 1 rats.
The addition of amiloride to the infusate during the subse-
quent experimental period augmented the early segment PD to
+ 12.2 0.6 mV (N = 36, P < 0.001) and abolished the negative
control PD in late segments, resulting in a small positive PD of
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Fig. 2. Distal transepithelial PD measurements (mean 5PM) in early
distal segments during distal tubular microperfusion using artificial
plasma ultrafiltrate (APU) j APU plus cisplatin , APU plus
cisplatin and amiloride , and APU plus amiloride . NS represents
not significant, and ** P < 0.001 when compared with APU. The PD5
obtained with the two perfusates containing amiloride did not differ
significantly.
+1.9 1.5 mY (N = 39, P < 0.001, Fig. 1), a value not
significantly different from zero. These results are similar to
those obtained during the experimental period of group 2
animals infused with cisplatin plus amiloride, suggesting that
amiloride prevents the effect of cisplatin on the late segment PD.
Group4: time controls—effect ofRingers bicarbonate infusion
without drugs. During the initial control period the mean PD in
early segments was +6.3 0.7 mY (N = 18), and in late
segments it was —21.0 2.1 mY (N= 19), which was similar to
control periods in groups 1 and 3. Continued infusion of Ringers
bicarbonate did not result in significant changes in the free-flow
PD yielding values of +6.8 0.9 mV (N = 12) for early
segments and —16.0 1.5 mV(N = 19) for late segments. (Fig.
1).
Microperfusion studies
Group 5: effect of cisplatin. Early and late distal tubules were
microperfused with either APU or APU plus cisplatin (Table 1).
During microperfusion with APU, a mean early segment PD
of —4.5 0.7 mV (N = 22) and a mean late segment PD of —12.4
1.2 mV (N = 21) were recorded. Previous studies have
provided strong evidence that these negative PDs are generated
principally by active electrogenic sodium transport [16, 20, 211.
The addition of cisplatin to the perfusate did not result in a
significant change in the early segment PD but caused a signifi-
cant increase in the late segment PD to —17.5 1.5 mV (N 24,
P < 0.01, Figs. 2 and 3).
Fig. 3. Distal transepithelial PD measurements (mean SEM) in late
distal segments during distal tubular microperfusion using artUlcial
plasma ultraflltrate (APU) , APU plus cisplatin , APU plus
cisplatin and amiloride , andAPUplus amiloride . Symbols are: *
P < 0.01; ** p < 0.001 when compared with APU. The PD5 obtained
with the two perfusates containing amiloride did not differ significantly.
Group 6: effect of amiloride plus cisplatin. Distal tubules
were microperfused with either APU plus amiloride or APU
plus amiloride and cisplatin (Table 1). Microperfusion with the
amiloride perfusate yielded an early segment mean PD of + 1.0
0.2 mV (N = 21) and a late segment PD of —3.2 0.5 mV (N
= 19). Thus, amiloride abolishes the negative PD of early
segments and substantially reduces the larger negative PD found
in late segments during perfusion with APU, presumably by
inhibiting electrogenic sodium transport [16, 20, 211.
When cisplatin was added to amiloride in the perfusate, a
mean early segment PD of +1.4 0.2 mY (N = 19) and late
segment PD of —3.6 0.7 mY (N = 17) were recorded. These
values were not significantly different from the PD5 observed
during microperfusion of APU plus amiloride alone. Thus, as
for the free-flow studies, amiloride prevented any augmentation
of the late segment PD by cisplatin (Fig. 2 and 3).
Discussion
The clinical use of cisplatin as a cytotoxic agent is somewhat
limited by its nephrotoxic side effects including acute tubular
necrosis and renal wasting of various electrolytes, resulting in
hypomagnesemia, hypocalcemia, and hypokalemia [1—121.
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Experiments using the isolated frog skin have demonstrated
that cisplatin augments active electrogenic sodium transport by
increasing apical membrane permeability to sodium ions [13]. A
similar effect has not been demonstrated in the mammalian
kidney, but in view of the proposed similarities between the
transport properties of the frog skin and the mammalian distal
nephron [251, such an effect on distal sodium transport might be
anticipated.
The present study investigates the effects of cisplatin on the
transepithelial PD of the distal nephron of the rat kidney and
clearly demonstrates that this drug substantially increases the
free-flow PD across late distal segments, previously shown to be
cortical collecting tubules [15, 20]. Indeed, infusion of cisplatin
resulted in a 68.6% rise in the late distal free-flow PD over
control levels. These free-flow PD results do not differentiate
between a direct effect of cisplatin on transport processes in the
distal tubule versus a more proximal action leading to altera-
tions in the rate of flow and/or ionic composition of fluid being
delivered to the distal tubule.
Microperfusion experiments were therefore performed to
control distal fluid delivery and composition. In these experi-
ments, a direct effect of cisplatin on the late distal PD was
found, consistent with an enhancement of active outward
sodium transport.
Our previous studies have shown that a component of the
negative PD normally present in late distal segments is derived
from active sodium reabsorption [16, 20, 211. Furthermore,
consistent with other sodium transporting epithelia,
electrogenic distal sodium transport is enhanced by aldosterone
and inhibited by amiloride and adrenalectomy [26—28]. The
increase in PD across late distal segments during luminal perfu-
sion with artificial plasma ultrafiltrate containing cisplatin is
consistent with stimulation of active sodium transport. As
suggested by van den Berg et al [13] in their study of the effect
of cisplatin on the frog skin, stimulation of distal sodium
transport might result from an increase in luminal permeability
to sodium ions, rather than a direct effect on the sodium-
potassium active ion pump located at the basolateral side of the
tubular cell. In the frog skin study, cisplatin caused a 40% rise
in short-circuit current and active sodium transport, It is of
interest that the increase in late distal PD induced by cisplatin
perfusion in our study is of similar magnitude (41.1%).
The ability of amiloride to reverse the effect of cisplatin on
the late distal PD was investigated in both free-flow and
microperfusion studies. In the free-flow studies, amiloride
abolished the late distal free-flow PD, both in the presence
(group 2) and absence (group 3) of cisplatin (Fig. 1). These
results indicate that amiloride prevents the stimulatory effect of
cisplatin on the late distal free-flow PD. Further support for this
conclusion is obtained from the microperfusion experiments of
groups 5 and 6 in which amiloride was shown to markedly
reduce the microperfusion PD, both in the presence and absence
of cisplatin (Figs. 2 and 3). Amiloride and cisplatin may
therefore interact via the same sodium pathway, as suggested
by van den Berg et al [131. These investigators concluded that in
the frog skin, cisplatin increased apical sodium conductance via
an amiloride-sensitive sodium channel.
In the present study, significant changes in the transepithelial
PD were not observed in early distal segments following
cisplatin administration either under free-flow conditions or
during microperfusion with plasma ultrafiltrate. Although
amiloride-sensitive sodium transport occurs in the early distal
tubule as well as in the late distal tubule [161, it is possible that
sodium reabsorption in early segments may be close to satura-
tion even under control conditions, thereby preventing any
enhancement of the PD with cisplatin.
It is well recognized that the distal nephron is the major site
for potassium secretion in the mammalian kidney. Further-
more, it has shown that an increased late distal PD might favor
potassium movement into the lumen of the tubule by voltage-
dependent mechanisms. The increased late distal PD induced by
cisplatin might therefore contribute to renal potassium wasting
and explain partially the hypokalemia observed in various
clinical trials [10, 11, 29].
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